We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
-5.89%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$266M
AUM Growth
-$65.2M
Cap. Flow
-$10.3M
Cap. Flow %
-3.88%
Top 10 Hldgs %
77.45%
Holding
39
New
3
Increased
16
Reduced
10
Closed
7

Top Buys

1
BMY icon
Bristol-Myers Squibb
BMY
+$19.5M
2
PTCT icon
PTC Therapeutics
PTCT
+$10.5M
3
MDCO
Medicines Co
MDCO
+$8.91M
4
USO icon
United States Oil Fund
USO
+$7.45M
5
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$4.31M

Top Sells

1
GLD icon
SPDR Gold Trust
GLD
+$10.4M
2
ACHN
Achillion Pharmaceuticals
ACHN
+$10.2M
3
INCY icon
Incyte
INCY
+$10.2M
4
ARWR icon
Arrowhead Research
ARWR
+$8.21M
5
HRTX icon
Heron Therapeutics
HRTX
+$6.66M

Sector Composition

1 Healthcare 89.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$40.5M 15.25%
849,043
+23,063
+3% +$1.23M
BMY icon
2
Bristol-Myers Squibb
BMY
$124B
$33.1M 12.45%
565,888
+356,187
+170% +$19.5M
ALNY icon
3
Alnylam Pharmaceuticals
ALNY
$37.8B
$29.5M 11.12%
789,208
-159,078
-17% -$6.66M
BCRX icon
4
BioCryst Pharmaceuticals
BCRX
$2.31B
$25.8M 9.72%
4,078,895
-125,684
-3% -$654K
LJPC
5
DELISTED
La Jolla Pharmaceutical Company
LJPC
$19M 7.17%
1,086,037
-84,114
-7% -$1.61M
AGEN
6
Agenus
AGEN
$208M
$17.3M 6.53%
214,513
+3,496
+2% +$343K
MDCO
7
DELISTED
Medicines Co
MDCO
$12.7M 4.78%
374,263
+251,263
+204% +$8.91M
PTCT icon
8
PTC Therapeutics
PTCT
$6.51B
$10.9M 4.1%
+997,166
New +$10.5M
INCY icon
9
Incyte
INCY
$23.3B
$8.7M 3.27%
86,757
-104,394
-55% -$10.2M
OXFD
10
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$8.12M 3.06%
543,287
+307,387
+130% +$4.31M
USO icon
11
United States Oil Fund
USO
$2.45B
$7.91M 2.98%
+84,375
New +$7.45M
BLUE
12
DELISTED
bluebird bio
BLUE
$7.56M 2.85%
9,463
+2,690
+40% +$2.14M
DRNA
13
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$5.88M 2.21%
2,043,216
+16,322
+0.8% +$58K
MASI
14
DELISTED
Masimo
MASI
$5.45M 2.05%
80,900
+55,000
+212% +$3.38M
ATRA icon
15
Atara Biotherapeutics
ATRA
$78.6M
$5.29M 1.99%
14,905
-3,420
-19% -$1.45M
CORI
16
DELISTED
Corium International, Inc.
CORI
$4.47M 1.68%
1,101,045
+55,298
+5% +$276K
RGNX icon
17
Regenxbio
RGNX
$579M
$4.45M 1.67%
239,789
+1,049
+0.4% +$20K
VIVE
18
DELISTED
VIVEVE MED INC
VIVE
$4.32M 1.63%
840
+1
+0.1% +$5.95K
TCMD icon
19
Tactile Systems Technology
TCMD
$663M
$4.08M 1.54%
248,762
+21,163
+9% +$367K
IVTY
20
DELISTED
Invuity, Inc
IVTY
$2.62M 0.98%
454,900
+62,062
+16% +$519K
OMER icon
21
Omeros
OMER
$667M
$2.57M 0.97%
259,039
-123,973
-32% -$1.27M
ACHN
22
DELISTED
Achillion Pharmaceuticals
ACHN
$1.18M 0.44%
286,285
-1,922,464
-87% -$10.2M
CLDX icon
23
Celldex Therapeutics
CLDX
$2.78B
$848K 0.32%
15,977
-66,901
-81% -$3.81M
SRTS icon
24
Sensus Healthcare
SRTS
$49.6M
$645K 0.24%
122,803
-2,897
-2% -$16.9K
MRTX
25
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$616K 0.23%
129,697
+568
+0.4% +$3.09K
1
2

Similar funds

BEI
Benjamin Edwards Inc Clayton, Missouri $10.1B AUM 14.03% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return

RTW Investments's Q4 2016 Portfolio in Review

As of Q4 2016, RTW Investments held 39 positions worth $266M, down 20% from $331M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

RTW Investments withdrew a net $10.3M in Q4 2016, closing 7 positions and reducing 10 holdings. Its most notable exit was SPDR Gold Trust, an estimated $10.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 90% a quarter earlier.

Against the trend, RTW Investments opened a new position in PTC Therapeutics worth $10.9M.

  • RTW Investments's largest Q4 2016 buy was PTC Therapeutics: 997,166 shares worth $10.9M.
  • RTW Investments added most to Bristol-Myers Squibb in Q4 2016, an estimated $19.5M increase.
  • RTW Investments's biggest Q4 2016 reduction was Achillion Pharmaceuticals, cutting an estimated $10.2M.
  • RTW Investments fully exited SPDR Gold Trust in Q4 2016, selling an estimated $10.4M.
  • RTW Investments's ten largest holdings make up 77% of its $266M portfolio in Q4 2016.
  • RTW Investments opened 3 new positions and closed 7 in Q4 2016.
  • RTW Investments's portfolio value fell 20% quarter-over-quarter to $266M.

Based on RTW Investments's 13F filing for Q4 2016, filed 15 Feb 2017.